AI assistant
Haleon PLC Board/Management Information 2022
5111_mang_2022-07-22_5f1d0b3c-e267-4263-85f1-14ab4eb69b63.html
Board/Management Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 4672T
Haleon PLC
22 July 2022
22 July 2022
Haleon plc
Haleon announces appointment of joint corporate brokers
Haleon plc, a global leader in consumer health, is pleased to announce the appointment of Citigroup Global Markets Limited and UBS as its joint corporate brokers, with immediate effect.
ENDS
About Haleon
Haleon (LSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. The group employs over 22,000 people across 170 markets, who are united by Haleon's purpose - to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com
Contact Details
| Investor Relations | Media Relations | ||
| Sonya Ghobrial | +44 (0) 7392 784784 | Nidaa Lone | +44 (0) 7841 400607 |
| Emma White | +44 (0) 7823 523562 | Ross Whittam | +44 (0) 7796 204198 |
| Rakesh Patel | +44 (0) 7552 484646 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPPPUCAMUPPUBP